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Nitric oxide production by human proximal tubular cells: A novel
immunomodulatory mechanism? It is believed that human proximal
tubular cells may possess immunological function and play an important
role in a variety of renal disease states such as interstitial nephritis,
allograft rejection and drug induced nephrotoxicity. The role of cytokines
and nitric oxide in the human forms of these disease states is not clear. In
this study we examined the effect of stimulation with the cytokines IL-1j3,
TNF-a and IFN-y, individually and in combination, upon primary cultures
of human proximal tubular cells. Nitric oxide production increased
significantly within 24 hours following cytokine stimulation. This response
was inhibited, in a dose dependent manner, by L-NMMA. PCR amplifi-
cation of mRNA extracted from control and cytokine stimulated human
proximal tubular cells revealed a NOS product with a >97% homology
with human hepatocyte inducible nitric oxide synthase. The results of this
study clearly show that human proximal tubular cells, in primary culture,
are capable of producing nitric oxide in response to an immune challenge
secondary to the induction of nitric oxide synthase.
The primary functions of proximal tubular epithelial cells
(FTC) are the transport of electrolytes and water, together with
the recovery of carbohydrate and proteins from the glomerular
filtrate [1]. However, human proximal tubular (HPT) cells may
exhibit immunological functions including processing and presen-
tation of foreign antigen and production of cytokines [21. The
importance of these immunological actions of HPT cells are
uncertain but are likely to be involved in diseases such as
interstitial nephritis, allograft rejection, pyelonephritis and drug
induced nephrotoxicity [3] where the HPT cell is a target for
cytotoxic injury. Furthermore, HPT cells may play an active role in
inflammatory diseases (as do mesangial cells [4]) and may possess
other immunomodulatoiy functions. The recent discovery that
nitric oxide (NO) has immunomodulatory and cytotoxic actions
prompted us to examine the possible role of NO in the HPT cell.
NO was initially identified as a vasodilator (endothelium-
derived relaxing factor, EDRF) [I but has since been shown to
act as a neurotransmitter, to possess immunomodulatoty and
cytotoxic effects [6—8] and to mediate tissue damage [8]. These
cytotoxic actions of NO are mediated by high local concentrations
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of NO, produced by induction of a cytokine dependent, calcium
independent enzyme-inducible NO syrithase (iNOS) [9]. This
contrasts with the vascular actions of NO which are mediated by
low concentrations of NO produced by a calcium-dependent,
constitutively expressed form of the enzyme [6, 9]. In macro-
phages induction of NO production has diverse actions, including
killing of parasites and tumor cells [8, 10, 11], destruction of
pancreatic islets in experimental streptozotcin-induced diabetes
[8, 12, 131, and tissue injury in immune complex-mediated vascu-
litis [14]. Furthermore, in the experimental model of diabetes,
inhibition of NO production attenuates the progression of disease
[8, 12, 13]. Recent evidence suggests that NO is involved in the
pathogenesis of glomerulonephritis (GN) [15—171. Urinary nitrite
excretion (a marker of NO production) is increased [14] in animal
models of GN, glomeruli isolated from animals with experimental
nephritis produce more nitrite [16], and isolated glomerular
mesangial cells and infiltrating macrophages can produce NO in
response to inflammatory cytokines [10, 17—20]. Thus there is
substantial evidence that NO production is increased in GN,
although the contribution to tissue damage remains to be estab-
lished [17].
Since HPT cells are a target for immune mediated disease and
possess immunomodulatoty functions [3, 4], we investigated the
ability of HPT cells in culture to produce NO. The aims of this
study were: (i) to determine whether HPT cells can produce NO
in response to cytokine stimulation, (ii) to identify the regulatory
influences of cytokines implicated in inflammatory disease upon
NO production, and (iii) to determine whether the inducible NO
synthase gene is expressed by these cells when stimulated by
cytokines.
Methods
Human proximal tubular cell preparation
Human proximal tubular cells (HPT) were prepared from the
normal pole of human tumor nephrectomy specimens as previ-
ously described [21]. Briefly, 10 g of cortex was removed and
minced in Hanks 1 buffer to remove remaining blood. Cortical
fragments were then digested at 37°C for 60 minutes in Flanks II
buffer containing 0.2% collagenase A (Sigma, UK). Following
digestion the cell suspension was filtered through a 75 jm filter
and the suspension pelleted and washed in Hanks III buffer before
resuspension in Percoll buffer solution. This suspension was then
centrifuged at 4°C for 30 minutes at 13,000 r.p.m. (20,000 g).
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Following centrifugation the cell pellet was resuspended in ice-
cold complete Dulbecco's modified Eagle's medium/Ham's F12
nutritional supplement (1:1, DMEM/HF12; Sigma UK). Cells
were then plated onto 24 well plates at a density of 1 x io cells
per well and incubated at 37°C (in 95% 02, 5% CC7) until
confluence was achieved (approximately 7 days). Once confluent
the cells were incubated for 24 hours [20] with the cytokines IL-1/3
(10 g/ml), TNF-a (10 ng/ml), IFN-y (100 g/ml), PDGF (1, 10, 100
ng/ml), TGF-/3 (0.1, 1, 10 pg/ml) (all Boehringer, UK), IL-4 (0.1,
1, 10 lU/mI, Life Technologies, UK). Cytokines were used alone
or in combination, and cytokines with potentially inhibitory effects
(IL-4, TGF-13 and PDGF) were studied in cells stimulated by a
"cocktail" of IL-1/3 (10 M/ml), TNF-a (10 ng/ml) and IFN-y (100
a/ml). Media was then removed for estimation of nitrite produc-
tion. To demonstrate the presence of inducible nitric oxide
synthetase cells were also incubated with the three cytokine
"cocktail" in the presence of L-NMMA (Sigma; 1, 10, 100, 1000
gmol/liter) and nitrite production determined in the supernatant.
Nitric oxide production
NO production was determined by measurement of nitrite (as
an end product of NO metabolism [5, 9]) in the culture superna-
tant using the Greiss reagent [5, 201. Nitrite was determined by
absorbance at 570 nm in a multichannel spectrophotometer
(Titertek Multiscan MC, Titertek UK) and is expressed as nmoles
per million cells per 24 hours (mean sD).
Molecular biology of inducible nitric oxide synthase
Human proximal tubular cells were seeded into two 75 cm2
culture flasks (Costar, UK) at a density of 4 )< 10 per flask and
allowed to grow to confluence. Cells were then dissociated from
the tissue culture flasks with 0.1% trypsin/5 n EDTA, washed in
cold phosphate buffered saline (PBS) and transferred to a mi-
crofuge tube. RNA was extracted by standard methods (MAN IA-
TIS). Cells were lysed in Nonidet P-40 (0.5% vol/vol) Tris-
buffered saline at pH 8.6, with 20 mM vanadyl-ribonucleoside
complexes (Sigma). Nuclei were removed by centrifugation (5 mm
at 150 g) and proteins digested with proteinase K (50 sg/ml,
Boehringer Mannheim) in the presence of 2% SDS. Protein
fragments were extracted with phenol:chloroform, and RNA
collected by precipitation of the aqueous phase in ice-cold isopro-
panol. The pellet was washed three times in 70% ethanol, air
dried and resuspended in TE buffer (10 mi Tris, 1 mivi EDTA, pH
7.6). Nucleic acid purity was measured by spectroscopy at 260 and
280 ns'i. RNA was then reverse transcribed by incubating the RNA
template with four deoxynucleotides (Pharmacia; at concentra-
tions of 500 sM), 500 ng/vol oligo dT, and 200 units of Superscript
reverse transcriptase (Life Technologies, UK) in the supplied
buffer (50 mM Tris-HC1, pH 8.3), 75 mM KCI and 3 mivi MgCI2
with 0.02 M dithiothreitol (Sigma). The reaction was incubated at
37°C for one hour. eDNA products were recovered by gel
exclusion chromatography (Pharmacia nick columns; Pharmacia,
UK) and phenol:chloroform extraction, followed by ethanol pre-
cipitation and resuspended in water.
The eDNA was amplified by the polymerase chain reaction
(PCR) using degenerate primers for NOS and specific primers for
32-microglobulin as a semi-quantitative control. For NOS, degen-
erate oligonucleotide primers were designed based on the known
rat constitutive [22] and the mouse inducible [23] NOS eDNA
sequences. The sequences derived were (degeneracies in brack-
ets):
Upper 5' GG(CT) TGG TAC ATG (AG)GC AC(Cfl
GAG AT(CT') GG 3'
Lower 5' GilT (GC)A(AGC) CAT CIC CTG (AG)TG GAA (AGC)
AC (AG)GG 3'
The position of the upper primer was from 1317-1342 and
consisted of 26 base pairs, while the lower primer consisted of 27
base pairs at position 1652-1626. Using these primers the pre-
dicted size of the amplified eDNA product is 336 base pairs
including primers or 283 bp excluding primers.
For f32-microglobulin the following primers were used:
Upper: 5' CCA TGA TGC TGC flA CAT GTC TC 3'
Lower: 5' CCI TGA GGC TAT CCA GCG TAC TCC 3'
(All primers were synthesized by Oswell DNA services, Edin-
burgh, UK).
PCR amplification was performed using the Perkin Elmer
Cetus Gene Amp kit and a Perkin Elmer Cetus DNA thermal
cycler. Twenty-five microliter reactions containing reverse tran-
scribed mRNA, nucleotides; 200 gsi each dNTP, 1 unit of Taq
DNA polymerase and primers (at 0.2 aM each primer) in ampli-
fication buffer were prepared in "Geneamp" reaction tubes. The
samples were amplified through an amplification profile of 1 cycle
at 94°C for two minutes, 55°C for one minute, and 72°C for 90
seconds. This was followed by 33 cycles of 94°C for 50 seconds,
55°C for 60 seconds, 72°C for 90 seconds. A final cycle consisted
of 94°C for 50 seconds, 55°C for 60 seconds and 72°C for five
minutes. The reaction products were separated by gel electro-
phoresis and stained in ethidium bromide. Using these degenerate
primers a 336 bp product was amplified and sequenced directly
using an automatic sequencer (Applied Biosystems); the product
sequence was then compared with sequences for human inducible
hepatocyte NOS, mouse inducible NOS and rat constitutive NOS
held within the Genbank database using the GCG programs
through the facility at the UK human genome mapping project.
Statistics
Results are expressed as mean sD. Comparisons are by two
sample Student's t-test, with the Bonferroni correction for multi-
ple comparisons where appropriate.
Results
Cell culture
Cultured HPT cells grew in monolayers to confluence over a
period of approximately seven days and exhibited the typical
morphology and dome formation characteristic of proximal tubu-
lar cells, except for a decrease in the density of brush border villi.
We have previously demonstrated that such preparations of HPT
cells maintain the sodium-dependent glucose, anion and cation
transport mechanisms [21]. Human proximal tubular cells were
also characterized according to their cAMP response to added
PTH (10 M), vasopressin (10_a M) and calcitonin (10_6 M). Only
PTH stimulated the HPT cells to produce cAMP. Neither vaso-
pressin nor calcitonin had any significant effect upon cAMP
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Table 1. Enzyme and histochemical staining of confluent cultures of
human proximal tubular cells and renal tissue sections
Proximal
tubular
APAAP stain cells Kidney sections
Acid phosphatase Positive Proximal tubule
Leucine amino peptidase Positive Proximal tubule
Glucose 3 phosphate dehydrogenase Negative Distal tubule
CALLA Positive Proximal tubule
vWF Negative Vascular endothelium
Thy 11 Negative Mesangial cells,
interstitial cells,
fibroblasts
EMA Negative Glomeruli, Distal
tubule
Abbreviations are: CALLA, common ALL antigen; vWF, von Wille-
brand's factor; Thy 11, cortical thymocyte; EMA, epithelial membrane
antigen.
production when incubated with these HPT cells. Following
incubation with PTH cAMP levels increased from a baseline value
of 2.1 1.3 to 8.3 2.4 pmol/mg protein/hr (P < 0.01, N =6) and
the response was maintained for up to seven days [24]. Immuno-
histochemical and enzyme histochemical staining of the cells
forming the confluent monolayers revealed a similar pattern, in
close agreement, to the staining pattern found on fresh human
kidney tissue sections prepared at the same time as the HPT cell
isolation (Table 1).
Nitrite production
Incubation of human proximal tubular cells with individual
cytokines IL-1/3, TNF-a, or IFN-y had no effect on nitrite
production when compared to unstimulated cells (Fig. 1). Com-
binations IL-113 and TNF-a or IFN-y and TNF-cs were also
ineffective in stimulating the production of NO. Prolongation of
the stimulation for up to 48 hours also had no effect (data not
shown). However, the combination of IL-113 and IFN-y produced
a significant rise in NO production from 3.7 0.54 to 39.12 9.7
nmol/million cells/24 hr (P < 0.001, N = 6). The combination of
all three cytokines was more effective in stimulating NO produc-
tion than this combination (49.04 11.67 nmol/million cells/24 hr,
P < 0.001).
Inhibition of nitrite production
Incubation of human proximal tubular cells with the three
cytokine cocktail in the presence of incremental concentrations of
a specific inhibitor of NO synthase-L-NMMA (1 to 1000 .tmol/
liter) produced a dose-dependent reduction in NO production.
Nitrite production fell progressively from 44.8 2.2 (cytokine
cocktail) to 4.2 2.1 (1000 tM L-NMMA, P < 0.001, N = 6)
approaching control levels at this dose (Figs. 2 and 3).
Co-incubation of cytokine stimulated cells with increasing doses
of IL-4, PDGF and TGF-f3 also inhibited nitrite production. IL-4
decreased nitrite production progressively from 49.0 11.7
(cytokine cocktail) to 29.2 11.2 (100 IU/ml, P < 0.001, N = 6).
Treatment with PDGF decreased nitrite production from 53.6
8.1 to 22.6 10.1 (100 ng/ml, P < 0.001, N = 6). TGF-f3
decreased nitrite to 30.3 4.1 (10 pg/mI, P < 0.001, N 6).
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Fig. 1. Stimulation of nitrite (nitric oxide) production by the individual
cytokines IL-I!3, TNF-a and IFN-y and combinations of cytokines IL -1 /3
and TNF-a, IL-I /3 and IFN--y, IFN-y and TNF-cc; and a "cocktail" of IL-I 13,
TNF-a and IFN-y.
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Fig. 2. The inhibition of cytokine stimulated nitrite production by L-NMMA.
PCR results
The results of amplification of mRNA extracted from control
and cytokine stimulated PCT are shown in Figure 4. There was no
change in the expression of the control (J32-microglobulin) mRNA
but a 336 bp product was detected only in stimulated cells using
the degenerate primers based on NO synthase. Sequence analysis
of the NOS product obtained (Fig. 5) revealed more than 97%
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Fig. 3. Inhibition of cytokine stimulated nitrite production by IL-4, PDGF
and TGF-f
homology with the recently published sequence for human hepa-
tocyte inducible NOS, corresponding to positions 1317-1652 of
human hepatocyte iNOS cDNA [24]. There was less (78%)
homology with the human brain constitutive NOS sequence [25],
the mouse inducible NOS (88%) and rat constitutive (83%) NOS
held within the Genebank database.
Discussion
This study demonstrates that human proximal tubular cells in
culture can be reproducibly induced to secrete nitric oxide.
Production of NO is regulated by cytokines involved in immune
mediated disease and is inhibited by the NO synthase antagonist
L-NMMA, the pattern of regulation being similar to that reported
in other human cell lines. In addition, using RT-PCR, we have
shown that cytokines stimulate nitrite production by induction of
iNOS mRNA [26, 27].
Induction of NOS
Single cytokines had no effect on the production of nitrite;
combinations of two of TNF-a, IL-1f3 or IFN-y were also without
effect with the exception of the combination of IL-1f3 and IFN-y;
the use of all three cytokines produced a consistent (Fig. 1 to 3),
twentyfold increase in nitrite production. This pattern of stimu-
lation is similar to that which we have previously found for human
mesangial cells in culture [20], and human hepatocytes [25].
Non-human cell lines appear to be less stringent in their stimula-
tory requirements [10, 11, 18, 19]. For example, rodent macro-
phages require only IFN-y to produce large amounts of NO [10,
11,281. Renal cell lines have also been studied; rat mesangial cells
can be induced to produce NO in response to IFN-y alone [18, 19]
whereas tubular epithelial cells require a combination of high
doses of TNF-a and IFN-y (150 U/mI and 500 U/mI, respectively)
for reproducible stimulation. The most striking differences appear
to be between macrophages: those of rat origin are easily induced
[10, 11, 28], whereas there are several reports of the inability of
human macrophages to produce NO [291. The reasons for these
differences are not clear. It is possible that there are true
differences in the regulation of inducible NOS between cell types
within species and certainly between species. However, an alter-
native hypothesis is that several stimulatory influences may be
required in all cells and that the differences may lie in the ability
of some cells to produce additional cytokines which then act in an
autocrine manner. For example, rodent macrophages may pro-
duce TNF-a and IL-i in response to IFN-y [30]. In the present
study the relatively minor effect of addition of TNF-a to IL-1/3
and IFN-y, may reflect the ability of HPT cells to produce TNF-a
when stimulated by IL-1f3 [31]. More detailed studies on the
inducible NOS gene expression will be required to address the
regulation of iNOS. In vivo, and particularly in inflammatory
conditions, it is unlikely that PTC would he exposed to single
cytokines in isolation. All three of the cytokines which we have
found necessary for NOS induction will be produced by infiltrat-
ing lymphocytes, polymorphs and macrophages at sites of inflam-
mation [30, 321 and, despite the requirements for multiple cyto-
kines, induction of NOS in HPT cells is likely to be of
pathophysiological relevance.
Nitrite is a stable end-product of NO metabolism [5] and
therefore provides a useful marker for NO production in the
absence of a generally available direct assay. The ability of
L-NMMA, a specific NO synthase antagonist, to inhibit nitrite
generation indicates that nitrite is produced by NO synthase; this
finding and the dose-response relationship are consistent with
findings for inducible forms of NO synthase in other tissues [9].
Having established that NO synthesis can be induced in PTC we
sought to identify potentially inhibitory influences. TGF-/3, PDGF
and IL-4 have established inhibitory actions on inducible NOS in
other tissues [28, 33—36] and are involved in the pathogenesis of
inflammatory diseases including glomerulonephritis [4, 37, 38]
and allograft rejection [39]. PDGF inhibits NO synthesis by rat
mesangial cells [33], TGF-f3 and IL-4 both have potent inhibitory
actions on the production of NO by macrophages [28, 34, 35]. The
ability of all three to inhibit nitrite generation in HPT cells
suggests that inducible NOS is regulated in a similar manner to
other cell types.
At the time when this study was conceived there were no
published data on the sequence of inducible forms of human
NOS. We therefore designed degenerate oligonucleotide primers
based on knowledge of the conserved areas in mouse macrophage
inducible [231 and rat brain constitutive forms of NO synthase
[22], based on the assumption that human forms of the enzyme
would be likely to share similarities. The sequence for hepatocyte
inducible NOS has since been published [25], and our degenerate
primers share homology with the equivalent areas of mRNA for
this enzyme. Although the polymerase chain reaction may be
criticized on the basis that it is difficult to quantify, it is clear from
our data that only in cells stimulated with the three cytokine
"cocktail" reveal a band (Fig. 4). Thus, it is apparent that the gene
is "switched on" in response to cytokine stimulation.
The PCR product was sequenced using an automated analyzer
and fluorescine end labeling [26]. The product obtained shows
high homology with the inducible mouse enzyme and near identity
with the human hepatocyte inducible NOS. Therefore, although
the primers used may have detected either form of the enzyme, it
is apparent that only the inducible form is amplified in stimulated
cells.
NO produced by proximal tubular cells may have several
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Fig. 4. Ethidium bromide gel of the PCR product obtained in stimulated and control cells.
1301 AGGGTGCCCC TTCAAT GtTACATGGG CACAAGA AGTCCGGG 1350
AGTCCGGG
1351 ACTTCTGTGA CGTCCAGCGC TACAACATCC TGGAGGAAGT GGGCAGGAGA 1400
ACTTCTGTGA CGTCCAGCGC TACAACATCC TGGAGGAAGT GGGCAGGAGA
1401 ATGGGCCTGG AAACGCACAA GCTGGCCTCG CTCTGGAAAG ACCAGGCTGT 1450
ATGGGCCTGG AAACGCACAA GCTGNCCTCG CTCTGGAAAG ACCAGGCTGT
1451 CGTGAGATC AACA'NCTG TGATCCATAG TTTTCAGAAG CAGAATGTGA 1500
CGTTGAGATC AACATTGCTG TGCTCCATAG TTTCCAGAAG CAGAATGTGA
1501 CCATCATGCA CCACCACTCC GCTGCAGAAT CCTTCATGAA GTACATGCAG 1550
CCATCATGGA CCACCACTCG GCTGCAGAAT CCTTCATGAA GTACATGCAG
1551 AATGAATACC GGTCCCGTGG GGGCTGCCCG GCAGACTGGA TTTGGCTGGT 1600
AATGAATACC GGTCCCGTGG GGNCTNCCCG GCAGACTGGA NTTGGCTGGT
1601 CCCTCCCATG TCTGGGAGCA TCACC CTTTCACCAG GAGATGCTGA 1650
CCCTCCCATG TCTGGGAGCA TCACC
TACGTCCT GTCCCCTTTC TACTACTATC AGGTAGAGGC CTGGAAAACC 1700
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potentially conflicting actions. It is likely to have vasodilator
effects on adjacent vessels thus increasing blood flow and the
deliveiy of infiltrating cells to the tubular interstitium. In vitro and
in the rejecting allograft it has been suggested that NO may limit
Fig. 5. Nucleotide sequence of human hepatocyte
iNOS and human proximal tubule PCR iNOS
product showing the region of homology.
Underlined bases indicate the primer sites. The
human proximal tubule INOS shows 98.5%
homology with human hepatocyte iNOS.
the proliferation of infiltrating T lymphocytes [39, 40]. NO and
other nitrosovasodilators are known to limit proliferation of other
cell types [41]. Consistent with the antiproliferative actions of NO
is the observation that inhibition of NOS in experimental allograft
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rejection increases the cellular infiltrate and the severity of the
rejection process [7, 39, 40]. It is possible that NO produced by
PTC, and other cells which are the target for immune-mediated
injuly, acts to limit the proliferation of infiltrating cells. The
findings that PDGF, TGF-p and IL-4 reduce NO production is
also consistent with this hypothesis. In inflammatory states TGF-13
and PDGF are likely to be derived from infiltrating cells and
platelets [37, 38]; IL-4 is produced by T lymphocytes of the Th-2
subtype [32]. In inflammatory conditions these cytokines might act
to inhibit NO production by target cells and therefore permit
increased proliferation of infiltrating T cells. The other potential
action of NO is cytotoxic. There is abundant evidence that NO
production by macrophages is involved in destruction of parasites
and tissue [7, 8, 10—12] in immune-mediated disease. There is also
evidence that NO may cause auto-destruction of cells [42], and
therefore induction of NO synthesis in PTC may contribute to
damage to these and other renal cell types [17]. Inhibition of NO
synthesis may therefore have potentially deleterious or beneficial
effects in inflammatory conditions involving the HPT cell; future
studies will be required to determine the role of NO and of
pharmacological NOS inhibition.
Reprint requests to Dr. James McLay, Department of Medicine and
Therapeutics, Aberdeen Universi!y Medical School, Polwarth Building, For-
esterhill, Aberdeen AB9 2ZD, Scotland, United Kingdom.
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